Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_assertion type Assertion NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_head.
- NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_assertion description "[Short-term (30 min) pretreatment with forskolin (FSK; 10 muM), a direct activator of adenylyl cyclase, in combination with the cyclic nucleotide phosphodiesterase inhibitor isobutylmethylxanthine (IBMX; 200 muM), attenuated CCE in PASMC from normal subjects, patients without pulmonary hypertension (NPH), and patients with IPAH.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_provenance.
- NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_assertion evidence source_evidence_literature NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_provenance.
- NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_assertion SIO_000772 17189322 NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_provenance.
- NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_assertion wasDerivedFrom befree-2016 NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_provenance.
- NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_assertion wasGeneratedBy ECO_0000203 NP586023.RAlWR-cSXQzbK9xSE6jNruTIw5REapVOjlol-8zNRLD-Q130_provenance.